Literature DB >> 9689961

[Therapy of nodal positive prostatic carcinoma: when should hormone therapy be started?].

D Zierhut.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9689961     DOI： 10.1007/bf03038354

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

1.  Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.

Authors:  C A Lawton; K Winter; R Byhardt; W T Sause; G E Hanks; A H Russell; M Rotman; A Porter; D G McGowan; J D DelRowe; M V Pilepich
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-07-15       Impact factor: 7.038

2.  Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.

Authors:  A V Kaisary; C J Tyrrell; W B Peeling; K Griffiths
Journal:  Br J Urol       Date:  1991-05

3.  Role of Postradical Prostatectomy Irradiation in Carcinoma of the Prostate.

Authors: 
Journal:  Semin Radiat Oncol       Date:  1993-07       Impact factor: 5.934

4.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

Authors:  M V Pilepich; R Caplan; R W Byhardt; C A Lawton; M J Gallagher; J B Mesic; G E Hanks; C T Coughlin; A Porter; W U Shipley; D Grignon
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

5.  Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.

Authors:  D P Byar; D K Corle
Journal:  NCI Monogr       Date:  1988

Review 6.  Hormonal therapy for metastatic prostate cancer: issues of timing and total androgen ablation.

Authors:  M S Cookson; M F Sarosdy
Journal:  South Med J       Date:  1994-01       Impact factor: 0.954

7.  Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

Authors:  N J Vogelzang; G W Chodak; M S Soloway; N L Block; P F Schellhammer; J A Smith; R J Caplan; G T Kennealey
Journal:  Urology       Date:  1995-08       Impact factor: 2.649

Review 8.  The clinical usefulness of prostate specific antigen: update 1994.

Authors:  A W Partin; J E Oesterling
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450
  8 in total
  1 in total

1.  Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.

Authors:  Frank Kunath; Katrin Jensen; Mariona Pinart; Andreas Kahlmeyer; Stefanie Schmidt; Carrie L Price; Verena Lieb; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2019-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.